+

WO1988000056A1 - Composition et procede de castration et de sterilisation immunologiques - Google Patents

Composition et procede de castration et de sterilisation immunologiques Download PDF

Info

Publication number
WO1988000056A1
WO1988000056A1 PCT/AU1987/000199 AU8700199W WO8800056A1 WO 1988000056 A1 WO1988000056 A1 WO 1988000056A1 AU 8700199 W AU8700199 W AU 8700199W WO 8800056 A1 WO8800056 A1 WO 8800056A1
Authority
WO
WIPO (PCT)
Prior art keywords
lhrh
composition
animals
rams
protein
Prior art date
Application number
PCT/AU1987/000199
Other languages
English (en)
Inventor
Alan John Tilbrook
Robert John Fairclough
Original Assignee
The State Of Victoria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The State Of Victoria filed Critical The State Of Victoria
Priority to FI880954A priority Critical patent/FI880954A0/fi
Publication of WO1988000056A1 publication Critical patent/WO1988000056A1/fr
Priority to NO880918A priority patent/NO880918L/no
Priority to DK114588A priority patent/DK114588A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Definitions

  • the present invention relates to the suppression of social and sexual behaviour of male domestic animals and the suppression of ovulation and oestrous cyclicity of female domestic animals, and more specifically to a composition and method for immunological castration and spaying.
  • LHRH luteinizing hormone releasing hormone
  • LHRH is released from the hypothalamus into the pituitary portal vessels. It has been suggested that LHRH binds to the gonadotrophs of the anterior pituitary to stimulate secretion and release of luteinizing hormone (LH). LH acts on the Leydig cells in the testis to increase the production of testosterone. Active immunization against LHRH disrupts the communication between the hypothalamus and pituitary. It is thought that the site at which antibodies to LHRH might inhibit reproductive function is in the hypophyseal portal blood vessels (Schanbacher, 1984).
  • LHRH is a small peptide of 9 amino acids. In the field of immunology, it is well established that small immunogens elicit a poor immune response when injected into a host. Consequently, in each of the above studies, LHRH has been chemically conjugated to one particular carrier protein, for example, Human Serum Albumin.
  • the present applicants have surprisingly found that a synergistic interaction occurs when animals are immunised with a combination of two or more different carriers coupled to LHRH or analogues of LHRH.
  • Combinations of LHRH or analogues of LHRH conjugated with carriers elicit an effective immune reponse (measured in terms of antibody titre) in a greater proportion of animals than if LHRH or analogues of LHRH conjugated to a single carrier are administered.
  • compositions for the production in animals of antibodies specific for LHRH or analogues of LHRH comprising two or more different carriers individually coupled to LHRH or analogues of LHRH.
  • Analogues of LHRH are peptides where additions, deletions, modifications or alterations have been made to the natural sequence of LHRH. Alterations to the natural sequence include the addition of one or more amino acids to the amino or carboxy terminus of LHRH.
  • Domestic animal species falling within the scope of the invention include, cattle, sheep, goats, cats, guinea pigs, pigs, dogs, reindeer, horses and primates including women.
  • Carriers of any type which are useful immunogens may be utilised.
  • the carriers are proteins and more preferably the proteins are soluble in aqueous solution although precipitated protein may be used.
  • DT Diptheria Toxoid
  • HSA Human Serum Albumin
  • P.A. staphyloccus protein A
  • KLH Keyhole Limpet Haemocyannin
  • TT Tetanus Toxoid,
  • the carriers are proteins such as, HSA and P.A. or KLH and TT, each of these proteins being conjugated to LHRH.
  • two or more carriers where each carrier coupled to LHRH and separately administered toan animal elicits a generally good titre response.
  • compositions where one of the carriers is Diptheria toxoid (DT).
  • Other carriers that may be used in the present invention include lipopolysaccharides, polysaccharides, glycopeptides, muramyl peptide analogues, peptidoclycans [from bacteria cell walls], liposomes, lecithin like materials, and bacterial proteins for example purified protein derivatives from tuberculin.
  • the composition contains an adjuvant.
  • adjuvants which may be used are aluminium hydroxide, Freunds incomplete adjuvant, Freunds complete adjuvant, DEAE dextran, levamisole, PCG and polyA, polyC or polyU.
  • a mineral oil composition that includes bacterial cell wall material such as peptidoglycans, or a synthetic derivative of such a cell wall material. Such a synthetic material is known as muramyl dipeptide.
  • composition may be optionally buffered to physiological pH using buffers such as TRIS-HCl, Hepes, pipes or other appropriate buffers.
  • buffers such as TRIS-HCl, Hepes, pipes or other appropriate buffers.
  • a method for the suppression of male social and sexual behaviour of domestic animals comprising the administration of a composition to a domestic animal said composition comprising two or more different carriers individually conjugated to LHRH or analogues of LHRH.
  • Administration may be parenterally, for example, subcutaneous, and/or intramuscular or intravenous injection, orally or by absorption through the skin or by a mini-pump either implanted in the animal or attached to the outside of the animal.
  • bull calves are preferably immunised with the composition at between 8 to 40 weeks of age.
  • ram lambs are preferably immunised at 8 to 24 weeks.
  • Booster injections are preferably given eight weeks apart and preferably 1 to 3 booster injections are given.
  • the administration of the substance e.g. LHRH
  • the present invention has particular utility in the immunological castration and spaying of domestic pets or companion animals, particularly cats and dogs. Conventional surgical treatments performed by veterinarians may be expensive, and often traumatic for the animal involved and its owner.
  • An increase in the proportion of animals responding; may also occur where other substances that elicit an immune response, other than LHRH or analogues of LHRH, are conjugated to at least two different carriers and combinations of these conjugates are subsequently administered to animals.
  • peptides and proteins such as adrenocorticotrophic hormone, substance P, human chorionic gonadotrophin, somatostatin, epidermal and insulin-like growth factors; steroids including androstenedione (fecundin), testosterone and other substances such as melatonin and the prostaglandins.
  • LHRH Luteinizing hormone releasing hormone is a specific substance involved in stimulating luteinizing hormone and follicle stimulating hormone from the adenohypophysis.
  • Carrier Any substance, especially protein which, when coupled to small substances, can elicit an immune response to animals.
  • Antibody titre The dilution of antisera which binds 50% of 0.15 nCi 131 I-labelled LHRH for 16 h at 4°C. Precipitation of the gamma globulins was achieved using polyethylene glycol at a final concentration of 14.5%.
  • HSA Human serum albumin
  • CP Corynebacterium parvum.
  • P.A. Protein A from Staphylococcus aureus.
  • Carb 1-ethyl-3 (3-dimethyl aminopropyl) carbodiimide.
  • Glut Gluteraldehyde.
  • Figures 1, 2 show Antibody Titre (Log Scale) plotted against various treatment groups for ram lambs and bull calves respectively.
  • Figures 3 and 4 show mean testicular volume of ram lambs given Corynebacterium Parvum (CP), Keyhole Limpet Haemocyanim (KLH), Diphtheria Toxoid (DT), Testanus Toxoid (TT) and a combination of these carriers coupled to LHRH; CP, KLH, DT in Figure 4 and KLH, TT and DT in Figure 3.
  • CP Corynebacterium Parvum
  • KLH Keyhole Limpet Haemocyanim
  • DT Diphtheria Toxoid
  • TT Testanus Toxoid
  • LHRH (240 mg) and tetanus toxoid (35.5 ml, 248 mg) was dissolved with 20 ml distilled water and the pH of the mixture adjusted to 6.0 with 0.1 N NaOH.
  • a freshly prepared solution of 0.4 mg 1-ethyl-3 (3-dimethyl amino propyl) carbodimide hydrochloride (ECDI) in 2 ml distilled water has added dropwise and the reaction allowed to proceed at room temperature (22oC) overnight.
  • the solution was dialysed against 3 changes of saline (5 litres). To estimate the number of moles of LHRH bound to tetanus toxoid 3nCi of 131 I labelled LHRH was added into the reaction mixture.
  • the solution was dialysed against 3 changes of saline (5 litres).
  • a flock of 42 Merino ram lambs were used in the study.
  • the rams were selected by liveweight into 7 groups of 6 rams. (However during the course of the experiment some rams were lost; deaths were attributed to pneumonia). Treatments are shown below:
  • Each individual immunogen solution was emulsified with equal volumes of Freund's complete adjuvant.
  • the ram lambs were then given 2 ml of the mixture in 4 separate subcutaneous sites in the back leg adjacent to the groin.
  • the combined immunogens were injected with 8 ml of the emulsion.
  • Booster injections were made using identical quantities of freund's incomplete adjuvant.
  • a herd of 35 bull calves of predominently Friesian breed were used for the experiment. The calves were raised on skim milk and weaned onto grass at 10 weeks of age. The bulls were divided into 5 groups of 7 animals using liveweight as the basis of selection (during the course of the experiment three bulls were lost due to pneumonia). Treatments are shown below.
  • composition, dose and immunization schedule for the experiment is outlined in Table 2.
  • the immunogen solution was emulsified in an equal volume of Freund's complete adjuvant.
  • Freund's complete adjuvant For all individual treatment groups a total of 2 ml of the emulsion solution was injected into 4-5 sites.
  • the bull calves were injected into 4-5 sites with 8 ml of the emulsion solution. Injections were given subcutaneously near the front shoulder and the brisket of the calves.
  • the immunogens were emulsified using Freund's incomplete adjuvant. Blood samples were collected into heparinized containers at two weeks after the second booster injection. The antibody titres for this experiment are given in Table 4.
  • the behavioural data presented in Table 5 show that control animals spent more time involved in social and sexual behaviour and in social and sexual investigation than animals in the castrate, combination (LHRH individually coupled to KLH, TT and PA), and tetanus toxoid (TT coupled to LHRH) treatments.
  • LHRH individually coupled to KLH, TT and PA
  • TT tetanus toxoid
  • a flock of 80 Merino X Corredale rams at 5 months of age were used in this experiment.
  • the rams (16 weeks of age) were allocated to 8 groups of 10 rams. One group were surgically castrated at 16 weeks and another group were left as entire animals. The remaining 60 rams were treated with a number of LHRH antigens.
  • Various LHRH - carrier protein conjugates were prepared as described previously. The antigens used were LHRH coupled separately to diphtheria toxoid, tetanus toxoid, keyhole limpet haemocyanin and corynebacterium parvum. Two other groups were injected with two different combinations of the individual LHRH complexes.
  • Liveweights and testicular size (as determined using a series of calibrated beads) was measured every 4 weeks.
  • Antibody titre to LHRH were measured by both radioimmunoassay (RIA) and ELISA techniques.
  • Plasma samples were serially diluted with phosphosaline buffer (0.05M, pH 7.6). The diluted samples (100 ul) were added to 100 ul bovine gamma globulin (3% 9w/v) and
  • Liveweights of all rams are shown in Table 7. There were no significant differences among groups although the mean liveweight values for the immunised rams were higher than the castrated males but lower than the control rams.
  • the mean testicular volumes for each treatment are shown in Table 8 and Figures 3 and 4. There was considerable variation with each individual antigen treatment. The largest decrease for individual carriers was observed in the rams immunised against LHRH coupled to diptheria toxoid. The next best carriers were tetanus toxoid follwed by keyhole limpet haemocyanin and corynebacterium parvum. The two different combinations of 3 separate antigens gave lower testes volumes than each of the individual antigens.
  • the proportion of rams in each group that were sexually active at 2 months after the booster injection are shown in Table 10. Ten out of a total of 10 rams in the control group were showed sexual activity. The best single antigen was diphtheria toxoid with 1 of 9 rams sexually active. The order of effectiveness was diphtheria toxoid, tetanus toxoid, keyhole limpet haemocyanin and corynebacterium parvum. The two groups with the combined antigens were not sexually active. For those rams given a combination of TT, DT and KLH coupled to LHRH there were no rams active out of a total of 10 rams. Similar results were obtained using a different combination of carriers, DT CP and KLH where again there were no rams active out of a total of 8 rams (two rams died during the trial). None of the castrated rams were sexually active.
  • T974 Blockage of the preovulatory surge of LH and FSH and ovulation by anti-LHRH serum in rats. Endocrinology 95:323-325.
  • Clarke et al. (1978) Active immunization of ewes against luteinizing hormone releasing hormone, and its effect in ovulation and gonadotrophin, prolactin and ovarian steroid secretion.
  • Robertson et al. (1984) Immunological castration of young bulls for beef production. In “Manipulation of growth in farm animals” (Eds. Roche, J.F. and D'Callaghan, D.) pp. 137-145.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Une composition, permettant la production chez les animaux d'anticorps spécifiques à l'hormone de libération de l'hormone de lutéinisation (LHRH), comprend au moins deux vecteurs différents liés séparément à l'LHRH ou à des analogues de la LHRH, en quantités suffisantes pour déclencher une réponse immunitaire contre la LHRH. Lesdites compositions sont utiles pour supprimer chez les animaux domestiques le comportement sexuel et social des mâles et le cycle oestral et l'ovulation des femelles.
PCT/AU1987/000199 1986-07-03 1987-07-03 Composition et procede de castration et de sterilisation immunologiques WO1988000056A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FI880954A FI880954A0 (fi) 1986-07-03 1987-07-03 Komposition och foerfarande foer immunologisk kastrering.
NO880918A NO880918L (no) 1986-07-03 1988-03-02 Preparat og metode for immunologisk kastrering og sterilisering.
DK114588A DK114588A (da) 1986-07-03 1988-03-03 Sammensaetning og fremgangsmaade til immunologisk kastration og udboedning

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPH6721 1986-07-03
AUPH672186 1986-07-03
AUPH9205 1986-11-27
AUPH920586 1986-11-27

Publications (1)

Publication Number Publication Date
WO1988000056A1 true WO1988000056A1 (fr) 1988-01-14

Family

ID=25643122

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1987/000199 WO1988000056A1 (fr) 1986-07-03 1987-07-03 Composition et procede de castration et de sterilisation immunologiques

Country Status (6)

Country Link
EP (1) EP0274496A4 (fr)
JP (1) JPH01500900A (fr)
DK (1) DK114588A (fr)
FI (1) FI880954A0 (fr)
NZ (1) NZ220932A (fr)
WO (1) WO1988000056A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4003944A1 (de) * 1990-02-14 1991-08-22 Gerhard Dr Prinzhaus Synthetisches polypeptid: lh - rh -- klh (konjugat aus luteinisierendem hormon-releasing hormon und dem keyhole limpet haemocyanin
WO1992015330A1 (fr) * 1991-03-01 1992-09-17 Rhône Merieux Procede d'immunoneutralisation anti-lhrh des animaux domestiques males non castres et peptide pour cela
EP0578293A1 (fr) * 1992-06-18 1994-01-12 Akzo Nobel N.V. Protéine frangée (fimbrilline-P) de E.Coli comme porteur immunogène contre GnRH
EP0596959A4 (fr) * 1991-07-26 1995-02-22 Commw Scient Ind Res Org Systeme d'administration de vaccin peptidique produisant son propre adjuvant et production du vaccin.
US5403586A (en) * 1989-08-25 1995-04-04 Biotechnology Australia Ptl Ltd. LHRH-TraTp fusion proteins
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1998027111A1 (fr) * 1996-12-17 1998-06-25 Centro De Ingenieria Genetica Y Biotecnologia. (Cigb) Vaccin pour l'immuno-castration reversible des mammiferes
WO1998051339A1 (fr) * 1997-05-14 1998-11-19 Pasteur Merieux Serums & Vaccins Composition vaccinale multivalente a porteur mixte
EP1007084A4 (fr) * 1997-07-09 2003-07-02 Csl Ltd Composition immunogene de lh-rh et procedes concernant cette composition
EP3466441A3 (fr) * 2012-03-09 2019-06-19 Nord University Procédés immunologiques d'inhibition de la maturation gonade
WO2020051656A1 (fr) * 2018-09-12 2020-03-19 Ouro Fino Saúde Animal Ltda Polypeptide chimérique antigénique, construction génétique et composition antigénique pour l'immunocastration de mammifères non humains

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1239346A (fr) * 1985-06-04 1988-07-19 Gursaran P. Talwar Vaccin anticonceptionnel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 98, No. 17, issued 1983, April 25 (Columbus, Ohio, U.S.A.), DONNA L. VOGEL et al, 'Sertoli Cell Maturation is Impaired by Neonatal Passive Immunization with Antiserum to LHRH', Abstract No. 137896q. *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6019983A (en) * 1982-06-19 2000-02-01 Akzo Nobel N.V. Carrier system against GnRH
US5403586A (en) * 1989-08-25 1995-04-04 Biotechnology Australia Ptl Ltd. LHRH-TraTp fusion proteins
DE4003944A1 (de) * 1990-02-14 1991-08-22 Gerhard Dr Prinzhaus Synthetisches polypeptid: lh - rh -- klh (konjugat aus luteinisierendem hormon-releasing hormon und dem keyhole limpet haemocyanin
WO1992015330A1 (fr) * 1991-03-01 1992-09-17 Rhône Merieux Procede d'immunoneutralisation anti-lhrh des animaux domestiques males non castres et peptide pour cela
EP0501882A3 (en) * 1991-03-01 1992-10-14 Rhone Merieux Method of anti lhrh immunoneutralization of non-castrated male animals and peptide therefore
US5573767A (en) * 1991-03-01 1996-11-12 Societe Anonyme Method for improving the organoleptic qualities of the meat from uncastrated male domestic animals, vaccines which are usable in this method, new peptide, in particular for producing these vaccines and vaccination kit relating thereto
US5955080A (en) * 1991-07-26 1999-09-21 Commonwealth Scientific And Industrial Research Organisation Self-adjuvanting peptide vaccine delivery system and production thereof
EP0596959A4 (fr) * 1991-07-26 1995-02-22 Commw Scient Ind Res Org Systeme d'administration de vaccin peptidique produisant son propre adjuvant et production du vaccin.
EP0578293A1 (fr) * 1992-06-18 1994-01-12 Akzo Nobel N.V. Protéine frangée (fimbrilline-P) de E.Coli comme porteur immunogène contre GnRH
US5684145A (en) * 1992-06-18 1997-11-04 Akzo Nobel N.V. Carrier system against GNRH
US6303123B1 (en) 1994-01-27 2001-10-16 Aphton Corporation Methods for the treatment of hormone-dependent tumors with immunogens against gonadotropin releasing hormone
US6132720A (en) * 1994-01-27 2000-10-17 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1998027111A1 (fr) * 1996-12-17 1998-06-25 Centro De Ingenieria Genetica Y Biotecnologia. (Cigb) Vaccin pour l'immuno-castration reversible des mammiferes
FR2763244A1 (fr) * 1997-05-14 1998-11-20 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
WO1998051339A1 (fr) * 1997-05-14 1998-11-19 Pasteur Merieux Serums & Vaccins Composition vaccinale multivalente a porteur mixte
US7862823B1 (en) 1997-05-14 2011-01-04 Sanofi Pasteur S.A. Multivalent vaccine composition with mixed carrier
US8029798B2 (en) 1997-05-14 2011-10-04 Sanofi Pasteur S.A. Multivalent vaccine composition with mixed carrier
EP1007084A4 (fr) * 1997-07-09 2003-07-02 Csl Ltd Composition immunogene de lh-rh et procedes concernant cette composition
EP2196213A1 (fr) * 1997-07-09 2010-06-16 Pfizer Inc. Composition immunogène de LHRH et procédés concernant cette composition
EP3466441A3 (fr) * 2012-03-09 2019-06-19 Nord University Procédés immunologiques d'inhibition de la maturation gonade
WO2020051656A1 (fr) * 2018-09-12 2020-03-19 Ouro Fino Saúde Animal Ltda Polypeptide chimérique antigénique, construction génétique et composition antigénique pour l'immunocastration de mammifères non humains

Also Published As

Publication number Publication date
FI880954L (fi) 1988-03-02
FI880954A0 (fi) 1988-03-02
EP0274496A1 (fr) 1988-07-20
DK114588A (da) 1988-05-03
EP0274496A4 (fr) 1989-12-19
NZ220932A (en) 1990-05-28
DK114588D0 (da) 1988-03-03
JPH01500900A (ja) 1989-03-30

Similar Documents

Publication Publication Date Title
US5573767A (en) Method for improving the organoleptic qualities of the meat from uncastrated male domestic animals, vaccines which are usable in this method, new peptide, in particular for producing these vaccines and vaccination kit relating thereto
CA2255888A1 (fr) Modulation de l'activite d'hormones ou de leurs recepteurs - peptides, anticorps, vaccins et utilisations correspondantes
AU602187B2 (en) Anti-reproductive hormone
WO1988000056A1 (fr) Composition et procede de castration et de sterilisation immunologiques
Lincoln et al. Antler growth in male red deer (Cervus elaphus) after active immunization against LH-RH
US20020187925A1 (en) Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
JP2001509489A (ja) 免疫原性ｌｈｒｈ組成物およびそれに関する方法
AU7642387A (en) Composition and method for immunological castration and spaying
Goubau et al. Immunization of sheep against modified peptides of gonadotropin releasing hormone conjugated to carriers
US4331657A (en) Fecundity of domestic livestock
GB2166951A (en) Steroidal immunogens for increasing ovulation in sows
Robertson et al. Immunological castration of young bulls for beef production
US4457914A (en) Fecundity of domestic livestock
NO880918L (no) Preparat og metode for immunologisk kastrering og sterilisering.
WO2000025831A1 (fr) Compositions et procedes ameliores servant a augmenter la productivite d'especes agricoles utiles
US5401829A (en) Biologically active molecules
NZ196126A (en) Increasing ovulation rate in female cattle
Croker et al. The immunization of ewes against steroids as a means of increasing prolificacy in a mediterranean environment
EP0072880B1 (fr) Composition pour le contrôle de l'ovulation chez les bovins féminins
AU738528B2 (en) Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
AU600014B2 (en) Reduction of reproductive losses
Chang THE REGULATION OF REPRODUCTION IN CATTLE BY AN ANTIESTROGEN, OR ACTIVE IMMUNIZATION AGAINST PROSTAGLANDIN F (2ALPHA) AND OVARIAN STEROIDS
O'Connell Immunization Against Gonadotropin Releasing Hormone Alters Puberty, Secretion of Luteinizing Hormone and Ovarian Activity in Beef Heifers�
Hoskinson et al. Hormone immunoneutralization and the manipulation of animal productivity: a perspective.
Stevens LHRH fusion protein vaccines in beef heifers and bovine ectopic ovarian xenografting

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 880954

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1987904375

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1987904375

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1987904375

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载